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Kidney function in metabolism is often underestimated. Although the word “clearance”
is associated to “degradation”, at nephron level, proper balance between what is truly
degraded and what is redirected to de novo utilization is crucial for the maintenance of
electrolytic and acid–basic balance and energy conservation. Insulin is probably one of
the best examples of how diverse and heterogeneous kidney response can be. Kidney
has a primary role in the degradation of insulin released in the bloodstream, but it is also
incredibly susceptible to insulin action throughout the nephron. Fluctuations in insulin
levels during fast and fed state add another layer of complexity in the understanding of
kidney fine-tuning. This review aims at revisiting renal insulin actions and clearance and
to address the association of kidney dysmetabolism with hyperinsulinemia and insulin
resistance, both highly prevalent phenomena in modern society.
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INTRODUCTION
Insulin is a vital hormone with several functions among which its central role in energy and
glucose homeostasis is fundamental (Plum, 2006). Beyond the traditional crosstalk between the
most recognized insulin-responsive organs (liver, adipose tissue, and skeletal muscle), kidney
insulin action and resistance have recently been suggested as critical components of metabolic and
Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphosphate; CEACAM-1, carcinoembryonic antigen-related
cell adhesion molecule 1; cGMP, cyclic guanosine monophosphate; CKD, chronic kidney disease; CV, cardiovascular; DKD,
diabetic kidney disease; DNL, de novo lipogenesis; eGFR, estimated glomerular filtration rate; ENaC, epithelial sodium
channel; ER, endoplasmic reticulum; FFA, free fatty acid; FoxO1, forkhead box O1; GBM, glomerular basement membrane;
GIT, glutathione-insulin transhydrogenase; GLUT1, glucose transporter 1; GLUT2, glucose transporter 2; GLUT4, glucose
transporter 4; GRB2, growth factor receptor-bound protein 2; GSK3, glycogen synthase kinase 3; GSV, GLUT storage vesicle;
IDE, insulin-degrading enzyme; INSR, insulin receptor; IR, insulin resistance; IRS1, insulin receptor substrate 1; IRS2, insulin
receptor substrate 2; MAPK, mitogen activated protein kinase; mTOR, mammalian target of rapamycin; NAFLD, non-
alcoholic fatty liver disease; NBCe1, sodium bicarbonate cotransporter 1; NHE-3, sodium/hydrogen exchanger 3; NKCC2,
sodium-potassium chloride cotransporter-2; PGC1α, peroxisome proliferator-activated receptor-γ coactivator 1α; PI3K,
phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5 biphosphate; PIP3, phosphatidylinositol 3,4,5 triphosphate;
PKB, protein kinase B; PKG, cGMP-dependent protein kinase G; PKGI, cGMP-dependent protein kinase G isoform I; PPARγ,
peroxisome proliferator-activated receptor γ; PT, proximal tubule; PTEN, phosphatase and tensin homolog; PTP1B, protein
tyrosine-phosphatase 1B; SGK1, serum/glucocorticoid regulated kinase 1; SGLT, sodium-glucose transport proteins; SGLT2,
sodium-glucose co-transporter 2; SGLT2i, sodium-glucose co-transporter-2 inhibitors; SHIP2, SH2-domain-containing
inositol phosphatase 2; SREBP-1c, sterol regulatory element binding protein-1c; T1DM, type 1 diabetes mellitus; T2DM,
type 2 diabetes mellitus; TZDs, thiazolidinediones; Vamp2, vesicle-associated membrane protein 2.
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dysmetabolic states (Artunc et al., 2016). The important role
of insulin in the kidney is further corroborated by the
increased prevalence of chronic kidney disease in subjects
with type 2 diabetes mellitus (T2DM) and non-alcoholic
fatty liver disease (NAFLD; Musso et al., 2014; Kim et al.,
2018; Mok et al., 2019; Kiapidou et al., 2020). Furthermore,
the kidney can adjust the levels of essential players of
nutrient homeostasis such as glucose and insulin (Krebs, 1963;
Chamberlain and Stimmler, 1967).
First reports of insulin actions in the kidney were originated
in the 1950s (Farber et al., 1951). Since then, the knowledge
acquired has dramatically increased, nonetheless much remains
unveiled. It is now known that insulin impacts on tubular
glucose reabsorption (Nakamura et al., 2015). In fact, a
whole therapeutic class based on this mechanism was recently
developed. Additionally, hyperinsulinemia driven by pancreatic
hypersecretion and/or impairments in hepatic insulin clearance
could explain changes in glomerular filtration rates and increased
renal gluconeogenesis, which in turn causes fatty liver deposition
and, as a direct consequence, may lead to dysglycemia (Bril
et al., 2014; Naderpoor et al., 2017; Jung et al., 2018;
Bergman et al., 2019).
Kidney is, in fact, the most critical organ responsible for
insulin clearance after the liver (Elgee and Williams, 1954;
Narahara et al., 1958); still, its relevance in the maintenance
of proper insulinemia and insulin sensitivity is underestimated.
The control of insulin clearance/action exerted by the kidney is
complex. Furthermore, the diversity of insulin actions is only
possible thanks to the differentiation of specific kidney segments
in which insulin regulates different pathways. In this review, we
will briefly describe insulin production and its main actions in
the liver, adipose tissue, and skeletal muscle. Moreover, we will
focus on kidney and on renal insulin actions as well as insulin
clearance/degradation. Overall, this work aims at highlighting
the critical role of kidney-insulin interplay in the development
of dysmetabolism.
OVERVIEW OF INSULIN BIOSYNTHESIS
AND NON-RENAL ACTION AND
METABOLISM
The insulin gene (INS) is represented by only one copy in the
human genome, and its transcription is mainly regulated by the
same enhancers of other glucose-related genes (Andrali et al.,
2008; Gao et al., 2014). In pancreas β-cell, INS is first transcribed
as preproinsulin and, after cleavage and folding in the rough
endoplasmic reticulum (ER), proinsulin is formed (Hutton,
1994). The conversion into insulin occurs after the removal of
the c-peptide in the Golgi apparatus, with a final maturation
achieved by c-terminal amino acid elimination (Steiner, 2004).
Mature insulin is composed of A and B chains linked by two
disulfide bonds, with a third bond within A chain (Mayer et al.,
2007). For storage, insulin is complexed in hexamers with zinc,
and an actin network is involved in the organization of mature
insulin granules for first and second insulin secretion phases
(Kalwat and Thurmond, 2013).
Insulin secretion is triggered by cytoplasmic increments in
ATP levels, derived from glucose internalization and subsequent
metabolism (Prentki and Matschinsky, 1987). This increase
in ATP shuts down membrane ATP-sensitive K+ channels,
depolarizing plasma membrane, and activating voltage-gated
calcium channels (Detimary et al., 1998). Indeed, the resultant
Ca2+ influx seems to be necessary for the fusion of insulin
granules with the plasma membrane, ending up in its secretion
(Hou et al., 2009). The first wave of insulin secretion is composed
of primed granules that are in close proximity with plasma
membrane (Olofsson et al., 2002). However, most of these
granules remain more distant from the plasma membrane and
are further boosted with newly synthesized insulin that will
culminate in 75–95% of total insulin secretion in the second
phase (Kou et al., 2014).
With the insulin pools ready to be released, insulin secretion
does not occur in a constant manner, but in waves of 4–
5 min interval (Song et al., 2000). The pulsatile secretion profile
is considered primordial for proper insulin responsiveness, as
constant release would result in down-regulation of insulin
receptor (INSR) expression (Matveyenko et al., 2012). After
binding and activation of its receptor, insulin, as an anabolic
hormone, promotes increased biosynthesis of macromolecules
further needed to maintain energetic balance during nutrient
privation (Bedinger and Adams, 2015).
At cellular level, insulin mostly relies on the specific
bind to its transmembrane receptor to perform its actions
(Figure 1). Insulin receptor is a tyrosine kinase receptor
with two extracellular α subunits and two transmembrane β
subunits (Ye et al., 2017). Insulin binding to INSR produces
an autophosphorylation that leads to the internalization of the
complex and activation of downstream effectors. INSR substrate
1 (IRS1) and 2 (IRS2) are the main targets that intracellularly
coordinate insulin action (Thirone et al., 2006; Kubota et al.,
2016). In the liver, the activity of these proteins is differently
controlled by insulin. Although both IRS1 and IRS2 are degraded
after insulin activation, only IRS2 is transcriptionally repressed by
insulin activation (Hirashima et al., 2003). Further transduction
of insulin signaling occurs via phosphatidylinositol 3-kinase
(PI3K)/AKT phosphorylation. AKT or Protein kinase B (PKB)
are considered the main effectors of metabolic insulin actions
(Taniguchi et al., 2006; Molinaro et al., 2019). On the other hand,
AKT1 and 3 are the leading players of mitogenic effects of insulin
by RAS/mitogen activated protein kinase (MAPK) cascade and
crosstalk with growth hormones (Xu et al., 2006; Xu and Messina,
2009; Qiu et al., 2017).
Given the scope of this review, we will summarize insulin
actions on non-renal target organs, but detailed information is
available in recent reviews (Gancheva et al., 2018; Tokarz et al.,
2018). The first organ to be reached by insulin is the liver, where
50–70% is removed at first pass (Duckworth et al., 1998). In
hepatocytes, insulin signaling recruits forkhead box transcription
factor 1 (FoxO1) to the cytoplasm, inhibiting the transcription of
gluconeogenic enzymes (Ling et al., 2018). In such an abundance
of glucose, insulin also stimulates the synthesis of glycogen by
phosphorylation of glycogen synthase kinase 3 (GSK3), which
leads to dephosphorylation and activation of glycogen synthase
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FIGURE 1 | Canonical insulin signaling cascade. Insulin (gray circle) binds to its transmembrane kinase receptor at cell membrane and triggers insulin signaling
cascade. Insulin receptor present two isoforms with distinct affinity for insulin already associated to differential insulin internalization (INSR A and INSR B; Calzi et al.,
1997). Binding of insulin auto-phosphorylates INSR at Tyr-960. Further recruitment and phosphorylation of insulin receptor substrate (IRS) 1 and 2 will mostly result in
subsequent activation of phosphoinositide-dependent kinase 1 (PDK1) through phosphoinositide-3 kinase (PI3K; Yamada et al., 2002). PDK1 is responsible for
propagation of insulin signal to one of the most important downstream effectors, Akt. Importantly, Akt has two distinct phosphorylation sites, Thr308 activated by
PDK1 (Alessi et al., 1997) and Ser473 phosphorylated by mammalian target of rapamycin complex (mTORC) 2 protein (Bayascas and Alessi, 2005). Finally, fully
activated Akt can interact with different proteins, eliciting different effects as stimulation of glucose uptake and glycogen synthesis by AS160 and glycogen synthase
kinase 3 (GSK3), respectively (Ng et al., 2008). On the other hand, INRS activation also promote growth factor receptor-bound protein 2 (GRB2) interaction with Shc
proteins and activation of mitogen activated protein kinases (MAPK; Skolnik et al., 1993; Xu et al., 2006). This as part of the insulin-mediated proliferative stimuli.
PIP2, phosphatidylinositol 4,5 biphosphate; PIP3, phosphatidylinositol 3,4,5 triphosphate.
(McManus et al., 2005). After the replenishment of liver glycogen
stores in the fed state, glucose starts to be degraded to pyruvate,
which is the precursor of lipid biosynthesis via de novo lipogenesis
(DNL; Sanders and Griffin, 2016). Herein, insulin signaling is
also crucial for upregulation of sterol regulatory element binding
protein 1c (SREPB1c), a transcription factor associated to further
transcription of DNL (Oh et al., 2003; Roder et al., 2007;
Krycer et al., 2010).
Only a fraction of the insulin that reaches the liver will
get to the periphery, to perform its action at skeletal muscle,
adipose tissue, and other insulin-sensitive organs. Skeletal muscle
is the greater insulin-dependent “kidnapper” of glucose, it is
responsible for ∼60 to 80% of whole-body glucose disposal
(DeFronzo et al., 1976; Fernandes et al., 2011). Insulin signals to
myocytes through classical signaling, promoting glucose uptake
by the dynamic translocation of glucose transporter 4 (GLUT4;
Zorzano et al., 1996). Glucose is here mainly used for glycolysis
or stored as glycogen as already described for the liver.
During the fed state, a clear inhibitory effect in lipolysis and
consequent blunt of free fatty acid (FFA) release is mediated
by insulin acting on adipocytes (Dimitriadis et al., 2011). The
resultant decrease in FFA availability reduces its hepatic uptake
and fatty acid oxidation, changing the disposal of substrates that
are mostly used for gluconeogenesis (Galgani et al., 2008). Not
exclusively for liver, the effect of insulin in reducing adipose tissue
FFA release is important for other organs that, at fed state, change
energy source to glucose and recover glycogen stores contributing
to normoglycemia (Petersen and Shulman, 2018). In this context,
glucose uptake is also stimulated by insulin in the fed state at
adipocytes. Furthermore, translocation of glucose transporters to
the membrane of adipocytes was very well characterized in 3T3-
L1 adipocytes by activation of the canonical PI3K/AKT2 pathway
(Ng et al., 2008).
As mentioned above, all these organs expressing INSR
are responsible for insulin clearance and local degradation.
However, a significant part of insulin degradation is played in
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the liver (50–70%) by its specialized machinery of internalization
and degradation (Najjar and Perdomo, 2019). In the case
of internalization, carcinoembryonic antigen-related cell
adhesion molecule 1 (CEACAM-1) phosphorylation by insulin
promotes rapidly receptor-mediated uptake (Poy et al., 2002).
Carcinoembryonic antigen-related cell adhesion molecule 1
expression occurs preferentially in liver, and restoration of its
function only at liver of null CEACAM-1 mice reverse the
hyperinsulinemia and fatty liver deposition observed in global
knockout CEACAM-1 model (Russo et al., 2017). Regarding
degradation, insulin-degrading enzyme (IDE) is considered the
most critical protease to cleave insulin intracellularly and is
highly expressed in the liver (Kuo et al., 1993).
The amount of insulin that remains in circulation after liver
first pass (30–50%) will be mostly degraded by the kidney
(Elgee and Williams, 1954; Narahara et al., 1958). However,
the kidney is not just an endpoint for insulin degradation, as
insulin also acts throughout the entire nephron. Whereas hepatic
insulin clearance is regaining attention as the very first alteration
leading to hyperinsulinemia, compensatory mechanisms that
could emerge from the kidney are not well known. Impairments
in hepatic insulin clearance increase peripheral insulinemia, and
very little is described regarding the exact effects of the increased
amount of insulin that will further reach the kidney.
KIDNEY AND INSULIN ACTIONS
Kidney works together with the liver for maintenance of optimal
insulin levels. In humans, kidney removes 6–8 U of insulin
per day by two major routes (Figure 2), that apparently
have distinct preferential physiological goals: post-glomerular
secretion (insulin signaling) and glomerular filtration (nutrient
conservation and homeostasis) (Ritz et al., 2013). In the kidney,
insulin acts at multiple sites along the nephron, from the
glomerulus (Coward et al., 2005; Welsh et al., 2010; Mima et al.,
2011; Lay and Coward, 2014) to the renal tubule (Tiwari et al.,
2008, 2013; Li et al., 2013), to modulate different functions
such as glomerular filtration, gluconeogenesis, renal sodium
handling, among others.
Many alterations in insulin associated mechanisms in the
kidney are driven by insulin resistance (IR), leading to diabetic
nephropathy if not reestablished (Svensson and Eriksson, 2006).
In the Asiatic population, it was described that the prevalence
of diabetic nephropathy with impaired estimated glomerular
filtration rate (eGFR) (with or without albuminuria) was 31.6%,
and the prevalence of albuminuria (with or without impaired
eGFR) was 16.9 and 22.0%, respectively (Mok et al., 2019).
Patients may already show diabetic kidney disease (DKD) at
the time of T2DM diagnosis. Nevertheless, 10 years after the
diagnosis of T2DM, low-level albuminuria is present in 24.9%
of the patients and 5.3% already present macroalbuminuria
(Adler et al., 2003).
Glomerular Insulin Actions
Podocytes are the primary constituent cell of the glomerulus, with
their long finger-like projections to the glomerular capillaries
at the glomerular basement membrane (GBM). These cells
have intercellular junctions that form filtration barriers to help
maintaining normal renal function. When damaged, podocytes
lose their arrangement resulting in a reduction in barrier
function. Indeed, one of the DKD features is the podocyte loss
with consequent albuminuria (Pagtalunan et al., 1997; Wolf
et al., 2005). Lately, it has been unveiled the role of insulin in
podocytes (Figure 3); in other words, podocyte IR gives rise to
the albuminuric feature.
Podocytes reveal to express proteins of the insulin signaling
canonical pathway, namely the INSR, and both IRS1 and IRS2
(Coward et al., 2005; Santamaria et al., 2015), with IRS2 being
the most prevalent one. Coward et al. (2005) depicted the effect
of insulin in human podocytes, which results in glucose uptake
not only through GLUT4 but also through glucose transporter
1 (GLUT1; Figure 3). As insulin promotes the translocation
of GLUT4 to the membrane through the activation of PI3K-
AKT2-PkB pathway, there is a remodeling of the cortical actin
of the cytoskeleton with subsequent contraction (Welsh et al.,
2010). In compliance, podocytes-specific deletion of INSR in
mice revealed DKD features based on substantial albuminuria
and histological features as podocyte foot structure loss and
glomerulosclerosis (Welsh et al., 2010). AKT seems to play a
central role as its phosphorylation appears to be severely affected
in several models of both type 1 diabetes mellitus (T1DM;
streptozotocin-induced T1DM) and T2DM (db/db mice, Zucker
rats) (Tejada et al., 2008; Mima et al., 2011). Moreover, AKT
isoform 2 deletion results in serious glomerular lesions in mice.
This can lead to rapid disease progression, also associated with
tubular dilatation and microalbuminuria (Canaud et al., 2013).
Other relevant players that might contribute to podocyte IR
is SH2-domain-containing inositol phosphatase 2 (SHIP2), a
down regulator of the PI3K signaling pathway shown to be
upregulated in the Zucker rats. Moreover, protein tyrosine-
phosphatase 1B (PTP1B), a negative regulator of the INSR
activity, or phosphatase and tensin homolog when increased,
appears to also compromise the insulin signaling pathway (Mima
et al., 2011; Garner et al., 2018).
Podocytes also present an insulin-dependent alternative
pathway, the cyclic guanosine monophosphate(cGMP)-
dependent protein kinase G (PKG), from which the PKG isoform
I-alpha levels are increased in glomeruli of the hyperinsulinemic
Zucker rats (Piwkowska et al., 2013). These high insulin levels
increase glomerular barrier albumin permeability through
a PKGI-reliant mechanism via the NAD(P)H-dependent
generation of superoxide anion.
An important player in podocytes physiology is the protein
nephrin, a podocyte-specific protein, which is responsible for
the maintenance of the integrity of the filtration barrier.
In fact, nephrin mutations are involved in severe nephrotic
syndrome (Lenkkeri et al., 1999). Nephrin appears to play a most
outstanding role in the trafficking of GLUT4 and GLUT1 by
interacting with Vamp2 as well as by interacting with insulin-
stimulated actin remodeling (Coward et al., 2007; Lay et al., 2017).
Of interest, nephrin can also induce phosphorylation of p70S6K
in a PI3K-dependent manner independently of INSR/AKT2
activation (Villarreal et al., 2016; Figure 3).
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FIGURE 2 | Continued
FIGURE 2 | Schematic representation of renal insulin handling. Insulin is
depicted in gray circles at different portions of the nephron. As insulin is a
small molecule, it will be fully filtered by the glomerular system until it reaches
the proximal tubule. At proximal tubule cells, almost all the filtered insulin will
be absorbed at the luminal membrane. In physiological conditions, only a
small percentage will be excreted in urine. Beyond glomerular filtration, insulin
also raise from the perivenous capillaries. In a closer look to the proximal
tubule cells is represented both mechanisms of insulin clearance. The
increased levels of insulin receptor (INSR) and consequent increased uptake
of insulin at the basolateral membrane is also depicted.
The development of glomerular IR is triggered by several
factors: high glucose and/or insulin levels, increased FFAs
levels, or an inflammatory milieu. Moreover, insulin signaling
appears to be relevant for the adaptative ER stress response
in DKD; this is the case for mice with podocyte-specific
heterozygous INSR deletion (Madhusudhan et al., 2015). In
support of this view, stable overexpression of INSR or knock-
down of PTP1B was protective against ER stress (Garner et al.,
2018). Podocyte mitochondria play an essential role in cellular
metabolism. When dysfunctional as a result of reactive oxygen
species production, mitochondria triggers apoptosis, which can
also be observed along with a compromised IR state (Susztak
et al., 2006). Certainly, the preservation or reestablishment of
podocyte integrity is essential in the prevention of the onset and
development of DKD.
INSULIN TUBULAR ACTIONS
In the kidney tubule, insulin has several roles: metabolism,
electrolyte and acid-base regulation and absorption of filtered
substances. However, the exact mechanisms by which insulin
performs these distinct roles is not fully understood. Nonetheless,
it seems that, at least some of them, are mediated by INSR, and
can be explained by the recruitment of specific IRS, as recently
shown by Nakamura et al. (2020) specifically for gluconeogenesis
and sodium reabsorption regulation. Still, there are overlapping
mediators in downstream pathways. In the following paragraphs
we will summarize the most relevant and well-known insulin
actions in the tubular segment.
Insulin receptor is present throughout the entire nephron
(Butlen et al., 1988; Stechi et al., 1994), however, insulin binding
capacity of luminal and basolateral membrane tubule cells is
different. There is evidence showing same affinity of INSR in
both membrane sides of the cell, nonetheless its abundance is
asymmetrical (Hammerman, 1985). In fact, the binding capacity
of the contraluminal compared to luminal membrane seems to
be several times greater due to higher expression of INSR (Talor
et al., 1982). Figure 4 summarizes insulin signaling in proximal
tubule (PT), regarding its actions in both gluconeogenesis and
sodium reabsorption. Additionally, insulin actions through INSR
are thought to be different in the proximal and distal nephron
regions. Tiwari et al. (2013) demonstrated, in a mouse model
with deletion of INSR in the kidney tubule cells, that depending
on the segment targeted with INSR deletion, there were different
phenotypes further described. In case of decreased INSR at PT,
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FIGURE 3 | Podocyte insulin signaling. Podocytes are the first cells to interact with insulin at the nephron and express several proteins of the canonical insulin
signaling pathway. However, here the podocyte-specific protein nephrin is known to have a role in the trafficking of glucose transporters (GLUT1 or GLUT4) to
podocyte membrane and consequently promote glucose uptake. The trafficking seems to involve Vamp2 and actin remodeling. On the other branch of insulin
signaling, an effect in the large-conductance Ca2+-activated K+ channels (BKCa) is also important for maintenance of podocyte integrity and proper glomerular
filtration. GRB2, growth factor receptor-bound protein 2; GSV, GLUT storage vesicle; VAMP2, Vesicle-associated membrane protein 2.
animals had a mild diabetic phenotype, without increased IR
when compared to control. These animals shown to have an
higher activity of gluconeogenesis enzymes (Tiwari et al., 2013).
On the other hand, in animals with the deletion of INSR targeted
to distal parts of the tubule, elevated blood pressure and impaired
sodium excretion was observed (Tiwari et al., 2008).
Glucose Reabsorption
Glucose is reabsorbed by the PT cells from the kidney tubule
lumen to the bloodstream (Figure 4A). In the kidney, GLUT2
is in the basolateral membrane and diffuses glucose out of the
cell, contrary to the liver, where GLUT2 acts in glucose uptake.
Sodium-glucose transporter proteins (SGLT) are responsible for
glucose and sodium co-transport by the luminal membrane of
kidney cells. Sodium-glucose co-transporter 2 (SGLT2) is a high-
capacity/low affinity sodium-glucose cotransporter present in the
apical membrane of proximal convoluted tubule cells (Vallon
et al., 2011). These transporters are responsible for approximately
90% of filtered glucose reabsorption, and an important target for
T2DM therapy (SGLT2 inhibitors; DeFronzo et al., 2012). The
remaining 10% of glucose in the tubule is absorbed by SGLT1,
a low capacity and high affinity sodium-glucose cotransporter
(Wright et al., 2011). Kidney has a threshold for glucose excretion
which, in healthy conditions, relates to a glycemic value around
180 mg/dl (Figure 4B). This threshold, however, can be altered
in diabetes (Rave et al., 2006). It is not clear if SGLT2 glucose
transport is or not directly dependent on insulin signaling
(Ferrannini et al., 2020). Nonetheless, SGLT2 expression was
shown to be upregulated by insulin on human cultured PT cells,
in a dose-dependent manner (Nakamura et al., 2015). Therefore,
in hyperinsulinemic states, frequently observed in prediabetes
and T2DM, an excessive glucose absorption can be observed. Of
notice, glucose is still highly absorbed by SGLT2 in IR states,
suggesting that this mechanism is not affected by IR, though
it is upregulated by hyperinsulinemia. In this case, a vicious
cycle can happen where increased insulin levels drive an increase
in glucose SGLT2 overexpression increasing glycemic levels
which in turn will increment the insulin secretion (Figure 4C).
Therefore, SGLT2 overexpression inhibition is a potential new
target for highly prevalent hyperinsulinemia related conditions,
namely some dysglycemic phenotypes and obesity. In this case,
lowering insulin levels could be paramount to prevent SGLT2
overexpression. Thus, SGLT2 inhibitors might become a relevant
therapeutic approach for hyperinsulinemia related conditions,
other than T2DM, namely obesity and prediabetes.
Gluconeogenesis Regulation
Kidney has a major role in gluconeogenesis along with the liver
and the intestine. Gluconeogenesis occurs mainly in PT cells
essentially from lactate and glutamine (Figure 4A). Moreover,
PT cells do not use glucose, as they get their energy mostly
from fatty acid oxidation (Gerich et al., 1963). Insulin regulates
gluconeogenesis in PT cells to meet the fluctuating needs of
the body. While in the fasting state the kidney contributes in
40% to overall gluconeogenesis, in the post-absorptive state its
contribution drops to 20% (Gerich et al., 1963; Figure 4B).
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FIGURE 4 | Dynamics of proximal tubule cells at fasting, fed and insulin resistant states. Proximal tubule cells are subjected to distinct microenvironments (lumen
and interstitium) and the regulation of absorption and reabsorption of molecules is complex. Although all the described processes occur in every cell of the proximal
tubule simultaneously, each specific process is illustrated in a different cell. At fasting (A), low levels of insulin allow expression of gluconeogenic enzymes whereas
sodium reabsorption is downregulated. Expression of glucose transporter 2 (GLUT2) at basolateral membrane is mostly associated to glucose output and not to its
uptake. Moreover, albumin absorption is performed by megalin and cubilin at luminal membrane and transcytosis allow albumin to be rerouted back to the organism.
At fed state (B), increased availability of insulin and glucose promote drastic changes in proximal tubule dynamics. In the case of insulin, luminal uptake is mostly
associated to degradation and basolateral to signaling activation. Insulin receptor (INSR) activation downregulates gluconeogenesis and increases sodium
reabsorption by different proteins as type 3 Na-H exchanger (NHE-3) and sodium-glucose transport protein 2 (SGLT2). Together with sodium, SGLT2 also
co-transport glucose from the lumen. Finally, hyperinsulinemia is linked to perturbations of proximal tubule cells in many aspects (C). As in many other organs, insulin
signaling desensitization is associated to inefficient inhibition of gluconeogenesis contributing to maintenance of increased levels of glucose. Derangements at
podocyte level increases filtration of albumin and overloads luminal capacity of reabsorption. Such impairment in albumin reabsorption culminates with albuminuria,
frequent observed in hyperinsulinemic states.
Nakamura et al. (2020) demonstrated that insulin
directly inhibits gluconeogenesis in isolated PT through
IRS1/AKT2/mTORC1/2, and that mTORC1 positively regulates
insulin signaling (Nakamura et al., 2020). Specifically, in the
fasting state, suppressed insulin signaling increases FoxO1
activity, increasing the expression of gluconeogenic genes, such
as PEPCK and glucose-6-phosphatase. In parallel, decreased
glucose reabsorption via SGLT2 on the luminal membrane
downregulates the NADH/NAD+ ratio, activating sirtuin
1 and peroxisome proliferator-activated receptor-gamma
coactivator 1α (PGC1α), a coactivator of FoxO1. Therefore,
these two mechanisms lead to enhanced gluconeogenesis.
On the contrary, in the fed state, the increased insulin
levels and glucose reabsorption result in the suppression of
gluconeogenesis through downregulation of the previously
mentioned gluconeogenic genes (Nakamura et al., 2015;
Sasaki et al., 2017). Whereas glucose is reabsorbed by the luminal
membrane, insulin interacts with the basolateral membrane, thus
gluconeogenesis regulation results from the integration of signals
from distinct cell microenvironment.
Sodium
Insulin impacts on the fine-tuning of several electrolytes by
the kidney. Among them sodium handling is probably the
best described (DeFronzo et al., 1975). However, the insulin
role on sodium retention in normoglycemia is not completely
established. Regulation of sodium absorption is paramount to
maintain the extracellular volume in a physiological range.
Kidney is the principal organ involved in sodium excretion,
responding and adapting to sodium intake (Krekels et al.,
2015). Additionally, sodium has a major role in driving
electrochemical forces that support kidney primary role in fine-
tuning body composition. Sodium reabsorption and excretion
results from the integration of a complex network of sensors,
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neural-hormonal stimuli and hemodynamic and metabolic
mechanisms (Frame and Wainford, 2017).
Contrary to glucose, sodium is absorbed along the nephron by
distinct apical sodium transport proteins. Usually, approximately
65% of filtered sodium is reabsorbed in the PT along with
water, mainly through type 3 Na-H exchanger (NHE-3) and
SGLT proteins. In addition, the thick ascending limb is
responsible for approximately 25% of reabsorption through
sodium-potassium chloride cotransporter-2 (NKCC2). Finally,
5–10% of sodium is reabsorbed in the collecting duct by epithelial
sodium channel (ENaC) and less than 10% is excreted in urine
(Esteva-Font et al., 2012).
The association of insulin with sodium absorption was
suggested almost a century ago (Atchley et al., 1933), nonetheless
discrimination of insulin- and glucose-mediated effects has
not been clarified (DeFronzo et al., 1976; Manhiani et al.,
2011). It is still under debate if insulin has a causal effect on
hypertension under normoglycemia. Nevertheless, it is known
that insulin stimulates sodium absorption in all the tubule
segments where it takes place (Kirchner, 1988; Friedberg et al.,
1991; Ghezzi and Wright, 2012). In the PT, insulin regulates
several sodium transporters, in both luminal (NHE-3, SGLT2)
and basolateral membrane (Na/K-ATPase, NBCe1; Figure 4A;
Gesek and Schoolwerth, 1991; Feraille et al., 1994; Ruiz et al.,
1998). Recently, Nakamura et al. (2020) showed that, regarding
sodium absorption in PT, insulin recruits an IRS (IRS2)
different from the one orchestrating gluconeogenesis (IRS1).
Insulin receptor substrate 2 acts through the AKT2/mTORC2
pathway (Nakamura et al., 2020; Figure 4A). In fact, mTORC2
is known to activate serum/glucocorticoid regulated kinase 1
(SGK1), that will then stimulate ENaC and NHE-3, increasing
sodium reabsorption (Satoh et al., 2015). It has been suggested
that, in healthy conditions, with rising insulin levels in fed
state, IRS2 desensitize, suppressing sodium reabsorption at PT
and increasing its delivery in the distal convoluted tubule
(Figure 4B). Moreover, with IR, the desensitizing mechanism is
abolished and therefore sodium will not reach the distal tubule
(Ecelbarger, 2020; Figure 4C). Of notice, by recruiting distinct
IRS, kidney cells can somehow dissociate pathways performing
distinct functions.
Finally, it must be kept in mind that insulin can interact with
intrarenal and systemic renin-angiotensin-aldosterone system in
several ways (Muscogiuri et al., 2008) and therefore, indirectly
interfere with sodium reabsorption in different mechanism out
of the scope of this review.
Albumin Absorption
The luminal membrane of PT cells is primarily responsible for the
reabsorption of proteins that are freely filtered in the glomerulus
by receptor-mediated endocytosis (Figure 4A; Christensen and
Gburek, 2004). This is the case of albumin reabsorption
that can have an important role in energy conservation. It
has been suggested that albumin endocytosis is a regulated
process, dependent on membrane receptors megalin and cubilin
(Christensen and Birn, 2001). More recent evidence suggest that
insulin might also have a role in the regulation of tubular albumin
absorption (Kumari et al., 2019).
Albuminuria is of major clinical relevance in diagnosis and
follow-up of kidney disease including subjects with diabetes.
Insulin resistance was found to be associated with decreased
INSR expression in tubular cells in rat models (Wang et al.,
2005). In these observations, Kumari et al. (2019) analyzed
urine samples from mice with targeted deletion of INSR from
the renal PT. These mice had an impaired uptake of albumin,
without any glomerulopathy. They also demonstrated that in
healthy humans, albumin absorption capacity and excretion vary
from the fast to the fed state. Moreover, IR was associated with
microalbuminuria even in normoglycemia as described in the
RISC study (Pilz et al., 2014) and thus can be present regardless
of diabetes diagnosis. Altogether, these evidences suggest that
albuminuria might be an important marker of kidney tubular
dysfunction and might reflect tubule cells IR (Figure 4C). These
reinforces the kidney contribution to diabetes development and
highlights insulin and albumin dynamics prior and regardless of
the development of diabetes.
KIDNEY INSULIN CLEARANCE
In the systemic circulation, besides insulin metabolization by
the liver, the kidney is the major site of insulin clearance
(around 25%) (Elgee and Williams, 1954; Narahara et al., 1958);
its action might be required to limit excessive insulin levels.
Evidences supporting this theory started to rise in the middle
of the 20th century (Zubrod et al., 1951; Elgee and Williams,
1954; Narahara et al., 1958; Ricketts and Wildberger, 1962).
In a study from 1966, Beck et al. (1966) found that when
insulin was injected intravenously in mice, it concentrated in
liver and kidney; however, with higher insulin doses, raised
insulin levels were found in rat’s kidney, while these levels were
found to be reduced in liver. Nevertheless, this early study
has some methodological limitations. Indeed, kidney insulin
clearance remains constant in spite of insulinemia variations,
but varies with creatinine clearance (Rubenstein et al., 1967).
Globally, these evidences suggest that kidney insulin clearance
is a non-saturable process, although dependent on glomerular
filtration rate.
Insulin freely filtered in the glomerulus is absorbed by the
lining cells of the PT (Figure 2). Upon entering the cell, insulin is
transported through the luminal membrane into the PT cells and
is degraded. Luminal insulin reabsorption limits urine insulin
excretion, thus less than 2% of insulin reaches the urine in
normal fasting conditions (Rubenstein and Spitz, 1968). Insulin
is transported through the luminal membrane by a receptor-
mediated endocytic mechanism (Rabkin et al., 1984). Endocytic
internalization of insulin seems to be more related to insulin
degradation than to insulin biological actions (Figure 2).
While glomerular filtration of insulin could not account for
its total estimated renal extraction, a second mechanism was
postulated. In this context, it was observed that a significant
amount of insulin was cleared by the post-glomerular peritubular
capillaries into the tubule cells (Chamberlain and Stimmler,
1967). In humans, this route represents around one-third of
cleared insulin in the kidney, where it enters tubule cells not
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just by endocytosis, but also by INSR mediated uptake. In this
case, through INSR binding, insulin signal to the kidneys’ tubular
apparatus is crucial to maintain central physiologic functions,
similarly to what happens in extra-renal tissues, namely regarding
glucose homeostasis and blood pressure.
Insulin degrading activity has been observed at cytosol,
lysosomes and mitochondria in addition to the membrane,
indicating that it occurs in distinct cell sites. Degradation at
the membrane level, however, seems to represent less than 2%
of total degrading activity (Rabkin et al., 1984). Insulin can
be initially hydrolyzed by an insulin protease followed by the
action of plasma-membrane-associated or lysosomal proteases.
This pathway can degrade insulin entering through both luminal
and contraluminal membrane. In another possible pathway,
endocytic vesicles containing insulin fuse with lysosomes. This
pathway comprehends glutathione-insulin transhydrogenase
(GIT) action, followed by hydrolysis of intact A and B chains by
lysosomal proteases, and seems to need insulin internalization. It
may act primarily on insulin delivered by luminal uptake and it is
most active when supraphysiological levels of insulin are present
(Rabkin et al., 1984).
Azizi et al. (2015) demonstrated that, in a culture of human
adipose microvascular endothelial cells, insulin can go through
microvascular endothelial cells by transcytosis (Azizi et al.,
2015). Regarding insulin handling in the kidney tubule, Dahl
et al. (1989) hypothesized that insulin molecules could also
pass tubular cells by a retroendocytic pathway instead of being
degraded. The authors demonstrated that cultured opossum
kidney cells exhibited a retroendocytic pathway for insulin
(Dahl et al., 1989). Using the same model, the authors later
demonstrated that inhibition of insulin degradation diverted
intact insulin from the degradative to the retroendocytic pathway
(Dahl et al., 1990). Although captivating, especially regarding a
potential contribution to hyperinsulinemic states, this hypothesis
was not further explored.
Whether insulin clearance mechanisms attributed to other
organs affects renal function and insulin clearance it is not clear.
For example, the lack of CEACAM-1, a key protein enrolled in
hepatic insulin clearance driving hyperinsulinemia, in the kidney
leads to increased renin levels contributing to a potentiation of
the RAS system and hypertension. These effects are exacerbated
upon high fat diet exposure. Hence, the described CEACAM-1
renal effects can be due to the lack of its expression as well as the
observed hyperinsulinemia (Huang et al., 2013; Li et al., 2015).
Despite early conflicting results, further studies showed that
insulin is excreted in urine. However, in physiological conditions,
it represents a minimal proportion of insulin filtered in the
glomerulus. In health, a minor amount of insulin appears in
the urine, as the majority is absorbed in PT. Tubule absorbing
capacity of insulin does not saturate and thus the insulin
fraction excreted in urine is constantly small, regardless of
insulin levels. However, the amount of insulin excreted in urine
varies physiologically (e.g., fasting and post-prandial) and in
pathological conditions (obesity, diabetes) depending on the
affected nephron region (e.g., glomerulopathy vs. tubulopathy)
(Rubenstein and Spitz, 1968). Considering that insulin is
internalized in the apical membrane by a receptor-mediated
endocytic mechanism, the increased urinary insulin excretion
might represent a tubular dysfunction. Subjects with tubulopathy
show large amounts of insulin in urine approximating the
amount that is filtered (Rabkin et al., 1984). Conversely, subjects
with nephrotic syndrome show normal amounts of insulin in
urine. When both glomerular and tubule lesion occur urine
insulin excretion increase (Rabkin et al., 1984).
CLINICAL INSIGHTS ON INSULIN
DYSREGULATION
Insulin resistance is a common feature in chronic kidney disease
(CKD) patients, even in absence of diabetes (DeFronzo et al.,
1981; Shinohara et al., 2002; Becker et al., 2005; Kobayashi et al.,
2005; Landau et al., 2011), and it is a risk factor for CKD
progression (Fox et al., 2004). Its prevalence in CKD ranges from
30 to 50%, and this mainly depends on the adopted method
of measurement (Spoto et al., 2016). Insulin resistance can be
detected at the very early stages, when eGFR is still within the
normal range, suggesting a potential role in triggering CKD
(Fliser et al., 1998). A large study based on the Atherosclerosis
Risk in Communities (ARICs) cohort confirmed that CKD
development increases in strict parallelism with the number of
metabolic syndrome criteria measured in non-diabetic adults,
and this relationship remains significant even after controlling
for the development of diabetes and hypertension (Kurella
et al., 2005). Insulin resistance has also been associated with
prevalent CKD and rapid decline in renal function in elderly,
non-diabetic, Asian individuals (Cheng et al., 2012), and with
microalbuminuria in the general population (Mykkänen et al.,
1998), and in patients with T1DM (Yip et al., 1993; Ekstrand
et al., 1998) and T2DM (Groop et al., 1993), indicating that this
relationship is independent of diabetes (Mykkänen et al., 1998;
Chen et al., 2003, 2004). The proposed mechanism by which IR
contributes to kidney damage involves the worsening of renal
hemodynamics through activation of the sympathetic nervous
system (Rowe et al., 1981), sodium retention, decreased Na+,
K+-ATPase activity, and increased GFR (Gluba et al., 2013).
The etiology of IR in CKD is multifactorial, depending
on classical and CKD-peculiar risk factors, such as physical
inactivity, inflammation and oxidative stress, adipokine
derangements, vitamin D deficiency, metabolic acidosis, anemia
and microbial toxins (Spoto et al., 2016).
Long-term hemodialysis has a positive effect on IR (DeFronzo
et al., 1978), but there is little clinical data regarding the effect of
peritoneal dialysis.
In addition to being a risk factor for CKD onset and
progression, IR is also involved in the increased cardiovascular
(CV) risk in this population. IR may be responsible for high blood
pressure via direct stimulation of renin–angiotensin–aldosterone
system (Nickenig et al., 1998), activation of sympathetic system
(Sowers et al., 2001) and downregulation of the natriuretic
peptide system (Sarzani et al., 1999).
However, the association between IR and CV complications
in CKD patients is still to be clarified, as well as the relationship
between IR and all-cause and CV mortality.
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A positive association between IR and all-cause mortality
was found in smokers and physically inactive CKD patients
(Xu et al., 2014) and in a small cohort of 170 Japanese,
non-diabetic, dialysis patients (Shinohara et al., 2002), whereas
association with CV mortality was found in a cohort of peritoneal
patients. However, no association was found in the ULSAM
cohort, including 3-4 stage CKD patients (Jia et al., 2014)
and in a small study performed in peritoneal dialysis patients
(Sánchez-Villanueva et al., 2013).
Even though the prognostic value of IR for death and CV
events need to be clarified, the association with CKD is well
established. Even in this case, however, if IR is responsible of the
onset and progression of CKD, or if CKD is responsible for IR is
still to be clarified. A possible answer to this question could derive
from clinical trials aiming at assessing the effect of drugs used for
IR treatment on kidney function.
Thiazolidinediones (TZDs) are a class of oral diabetic
medications that increase insulin sensitivity by acting on PPARγ
(Yki-Järvinen, 2004). The effect of TZDs on kidney function has
been previously described in mice models (Fujii et al., 1997).
Treatment with TZDs has been demonstrated to improve insulin
sensitivity in patients with T2DM after a 3-month treatment,
and to reduce albuminuria, the last effect likely mediated by
the concurrent increase in serum adiponectin concentration
(Miyazaki et al., 2007). These results were confirmed in a meta-
analysis of 15 double-blind, randomized, clinical trials involving
diabetic patients (Sarafidis et al., 2010) and in a large study
involving 4351 diabetic patients (Lachin et al., 2011). Even though
a meta-analysis reported an increase in cardiovascular mortality
linked to the use of TZDs in dialysis patients (Nissen and Wolski,
2007), no definitive proof are available on the risk related to this
medication in this population.
Another interesting class of hypoglycemic drugs with positive
kidney outcomes are the SGLT2 inhibitors (SGLT2i) which
inhibit glucose and sodium reabsorption in the PT (Ferrannini,
2017). These drugs have a renoprotective effect in patients with
T2DM (Perkovic et al., 2019) independently of glycemic control
(Cherney et al., 2017). The renal protective effect can also be
attributed to altered hemodynamics, reduced inflammation and
fibrosis as well as controlled blood pressure and weight loss
(Williams et al., 2020). In rats treated with SGLT2i the glycemic
improvement was accompanied by a decrease in insulin and lipid
levels (Huang et al., 2020). Moreover, the actions of SGLT2i
are associated with increased insulin sensitivity and decreased
albuminuria (Cherney et al., 2017). Interestingly, Jaikumkao
et al. observed that in an animal model of diet induced obesity
characterized by IR and impaired renal function dapagliflozin
treatment resulted in improved IR, renal function and renal
insulin signaling (Jaikumkao et al., 2018).
CONCLUSION
Insulin is a hormone which acts not only on the most recognized
insulin-responsive organs (liver, adipose tissue, and skeletal
muscle), but also on the kidney. Moreover, the kidney has a
primordial role in insulin clearance and may impact on insulin
plasma levels. Whereas its main action is mainly related to
homeostasis of glucose, including modulation of gluconeogenesis
and lipolysis, in kidney the effects of insulin and IR change
according to whether the target is in glomeruli or tubules. More
specifically, if in glomerular podocytes insulin promotes glucose
uptake, with an involvement in barrier permeability, in tubules
it contributes to glucose reabsorption and gluconeogenesis
regulation, and plays an important role in sodium homeostasis.
Importantly, insulin intervenes in albumin reabsorption
at tubular level. Moreover, IR has been associated with
microalbuminuria even in normoglycemia, and thus can be
present regardless of diabetes diagnosis. These findings reinforce
the kidney contribution to diabetes development and highlights
insulin and albumin dynamics prior and regardless of the
development of diabetes.
Insulin is cleared in the PT of kidney by two major routes,
either by absorption of filtered insulin, or by post-glomerular
capillary secretion, and only a minor amount appears to be
excreted in urine. A decreased renal insulin clearance might lead
to higher insulin levels, in the organ or systemically, favoring
IR. Nonetheless, the impact of renal insulin clearance affection
in the kidney or in insulin plasma levels still needs to be
further unveiled.
It is clear now that kidney is not a mere target of insulin action,
but insulin, more precisely IR, is also able to trigger CKD even in
absence of diabetes. IR has been associated with prevalent CKD,
rapid decline in renal function and microalbuminuria in the
general population and in diabetic patients. In addition to being
a risk factor for CKD onset and progression, IR is also involved
in the increased cardiovascular risk in this population. However,
if IR is responsible for the onset and progression of CKD, or
if CKD is responsible for IR is still to be clarified. Preliminary
confirmations come from clinical trials aiming at exploring the
effect of TZDs, a class of oral diabetic medications, on kidney
function. However, more focused studies, aiming also at testing
the safety of these medications in CKD patients, are needed to
better understand if treatment of IR may improve renal function
in this population.
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